Journals / Journal of Neurological Sciences (Turkish) / 2014 / Cilt: 31 - Sayı: 1

İnme Sonrası Distal Ekstremite Spastisitesinde Tekrarlanan A Tipi Botulinum Toxin Enjeksiyonlarının Etkinliği

Efficiency of Repeated Botulinum Toxin Type-A Injections in Post-Stroke Distal Limb Spasticity

Pages
21–27
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

But, the cumulative effect oftreatment was shown only in forearm pronators.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The purpose of this study was to assess cumulative effect of repeated Botulinumtoxin type-A (BT-A) injections in stroke patients with distal upper and lower limb spasticity.Methods: The patients were classified in 2 groups according to their upper and lower limbspasticity.
📊
Key Findings & Data:The degree of spasticity was measured with the modified Ashworth scale (MAS).The global assessment of treatment benefit was done by patient-reported improvement insymptoms as very good (75-100% improvement), good (50-74% improvement), moderate(25-49% improvement ), and insufficient (less than 25% symptom relief) at the final visit.MAS scores of each visits were compared.
💡
Conclusion & Impact:But, the cumulative effect oftreatment was shown only in forearm pronators.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The purpose of this study was to assess cumulative effect of repeated Botulinumtoxin type-A (BT-A) injections in stroke patients with distal upper and lower limb spasticity.Methods: The patients were classified in 2 groups according to their upper and lower limbspasticity. The degree of spasticity was measured with the modified Ashworth scale (MAS).The global assessment of treatment benefit was done by patient-reported improvement insymptoms as very good (75-100% improvement), good (50-74% improvement), moderate(25-49% improvement ), and insufficient (less than 25% symptom relief) at the final visit.MAS scores of each visits were compared. The patients started on injections within 1 yearafter stroke were considered as early treatment group. Early and late treatment groups werecompared in terms of effectiveness of the BT-A injections.Results: When MAS scores of the 5th injections were compared to those of 1st injections, thesignificant differences were only found in forearm pronator muscles (p=0.021). MAS scoresdecrease was more pronounced in early treatment group. The global assessment of treatmentbenefit was high in both groups (the upper limb spasticity group: 27% very good, 67% good;the lower spasticity group: 25% very good, 58% good).Conclusions: An increase in the benefit of regular BT-A injections in post-stroke patientswith distal upper and lower limb spasticity was observed. But, the cumulative effect oftreatment was shown only in forearm pronators.

Özet

Amaç: Bu çalışmada, distal üst ve alt ekstremite spastisitesi olan inmeli hastalardatekrarlanan A tipi Botulinum toxin (BT-A) enjeksiyonlarının birikici etkisini değerlendirmekamaçlanmıştır.Metodlar: Hastalar üst ve alt ekstremite spastisitesine göre iki grupta sınıflandırıldı.Spastisitenin derecesi modifiye Ashworth skalası(MAS) ile ölçüldü. Tedavi yararının globaldeğerlendirilmesi son vizitte hasta tarafından bildirilen belirtilerdeki düzelmeye göre çok iyi(%75-100 düzelme), iyi (%50-74 düzelme), orta (%25-49 düzelme) ve yetersiz (%25'inaltındaki belirti azalması) olarak oluşturuldu. Her vizitteki MAS skorları karşılaştırıldı. İnmesonrası 1 yıl içinde enjeksiyona başlanan hastalar erken tedavi grubu olarak kabul edildi.Erken ve geç tedavi grupları, BT-A enjeksiyonlarının etkinliği açısından karşılaştırıldı.Sonuçlar: Beşinci enjeksiyonun MAS skorları birinci enjeksiyonunkilerle karşılaştırıldığında,sadece ön kol pronatör kaslarında belirgin farklılıklar bulundu (p=0.021). MAS skorlarındakiazalma erken tedavi grubunda daha belirgindi. Tedavi yararının global değerlendirilmesi heriki grupta da yüksekti (üst ekstremite spastisite grubu: %27 çok iyi, %67 iyi; alt ekstremitespastisite grubu: %25 çok iyi, %58 iyi).Yorumlar: İnme sonrası distal üst ve alt ekstremite spastisitesi olan hastalarda düzenli olaraktekrarlanan BT-A enjeksiyonlarının yararında artış gözlendi. Fakat tedavinin birikici etkisisadece ön kol pronatörlerinde gösterildi.

🔖

Cite This Article

MATUR, Z., PARMAN, Y., HANAGASİ, A. H., ÇOBAN, A. (2022). İnme Sonrası Distal Ekstremite Spastisitesinde Tekrarlanan A Tipi Botulinum Toxin Enjeksiyonlarının Etkinliği. Journal of Neurological Sciences (Turkish), Cilt: 31 - Sayı: 1, 21–27. https://ajindex.com/articles/565024

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ashworth B. Preliminary trial of carisop odol in multip le sclerosis. Practitioner 1964;192:540- 2
  2. Bakheit AM, Fedorova N V, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L. The benef icial antisp asticity eff ect of botulinum toxin typ e A is maintained af ter rep eated treatment cycles. J Neurol Neurosurg Psychiatry 2004;75:1558-61
  3. Baricich A, Carda S, Bertoni M, Maderna L, Cisari C. A single-blinded, randomized p ilot study of botulinum toxin typ e A combined with non-p harmacological treatment f or sp astic f oot. J Rehabil Med 2008;40:870-2
  4. Barnes M, Schnitzler A, Medeiros L, Aguilar M, Lehnert-Batar A, Minnasch P. Eff icacy and saf ety of NT 201 f or upp er limb sp asticity of various etiologies--a randomized p arallel- group study. Acta Neurol Scand 2010;122:295- 302
  5. Bj ornson K, Hays R, Graubert C, Price R, Won F, McLaughlin JF, Cohen M. Botulinum toxin f or sp asticity in children with cerebral p alsy: a comp rehensive evaluation. Pediatrics 2007;120:49-58
  6. Cardoso E, Pedreira G, Prazeres A, Ribeiro N, Melo A. Does botulinum toxin imp rove the f unction of the p atient with sp asticity af ter stroke? Arq Neuropsiquiatr 2007;65:592-5
  7. Catz A, Barkol H, Steinberg F, Ronen J, Bluvshtein V, Keren O. Rep eated botulinum toxin inj ections can imp rove mobility in p atients with sp inal cord lesions. Eura Medicop hys 2007;43:319-25
  8. Chang CL, Munin MC, Skidmore ER, Niyonkuru C, Huber LM, Weber DJ. Eff ect of baseline sp astic hemip aresis on recovery of upp er-limb f unction f ollowing botulinum toxin typ e A inj ections and p ostinj ection therapy. Arch Phys Med Rehabil 2009;90:1462-8
  9. Cousins E, Ward A, Roff e C, Rimington L, Pandyan A. Does low-dose botulinum toxin help the recovery of arm f unction when given early af ter stroke? A p hase II randomized controlled p ilot study to estimate eff ect size. Clin Rehabil 2010;24:501-13
  10. Elia AE, Filipp ini G, Calandrella D, Albanese A. Botulinum neurotoxins f or p ost-stroke sp asticity in adults: a systematic review. Mov Disord 2009;24:801-12
  11. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C. Rep eated treatments with botulinum toxin typ e a p roduce sustained decreases in the limitations associated with f ocal upp er-limb p oststroke sp asticity f or caregivers and p atients. Arch Phys Med Rehabil 2008;89:799-806
  12. Gordon MF, Barron R. Eff ectiveness of rep eated treatment with botulinum toxin typ e A across diff erent conditions. South Med J